TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24798870
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg JNJ-41443532
Study: 22695756
Drug: Sublingual nicotine
Normalized name: nicotine Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual nicotine tablets (SNT)
Study: 20484175
Drug: β-carotene (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: β-carotene (20 mg per day)
Study: 15645186
Drug: Oral tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tramadol 50 mg (drops) followed by tramadol sustained release 100 mg orally, placebo rectally
Study: 15645186
Drug: Rectal tramadol
Normalized name: tramadol hydrochloride Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal tramadol 100 mg, placebo orally
Study: 31742316
Drug: Olive oil
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive oil (20 mL)
Study: 28089528
Drug: Hydrogel spacer
Normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrogel spacer infiltration into the rectal wall
Study: 26071975
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no β-blocker therapy)
Study: 14980926
Drug: PCEA (ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCEA (ropivacaine 3.2 mg plus fentanyl 8 microg/dose) with DM 90 mg
Study: 14980926
Drug: IV-PCA (morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV-PCA (morphine 2 mg/dose) with DM 90 mg
Study: 14980926
Drug: PCEA (ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCEA (ropivacaine 3.2 mg plus fentanyl 8 microg/dose) with placebo
Study: 14980926
Drug: IV-PCA (morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV-PCA (morphine 2 mg/dose) with placebo
Study: 25039272
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of sildenafil 100mg and vacuum erection device
Study: 20206891
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous (cIV) furosemide
Study: 20206891
Drug: Intermittent intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent intravenous (iIV) furosemide
Study: 17635508
Drug: Active lotion
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active lotion containing triethyl citrate and ethyl linoleate
Study: 2859075
Drug: Nine months'
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nine months' chemotherapy with rifampicin plus isoniazid supplemented by ethambutol for eight weeks
Study: 2859075
Drug: Eighteen months'
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eighteen months' chemotherapy with rifampicin plus isoniazid supplemented by ethambutol for eight weeks
Study: 23658561
Drug: Aerobic dance
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aerobic dance combined with drug therapy (Hydrochlorothiazide + amiloride hydrochloride, and Amlodipine)
Study: 23658561
Drug: Drug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug therapy (Hydrochlorothiazide + amiloride hydrochloride, and Amlodipine)
Study: 19842829
Drug: Condom availability
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Condom availability in treatment programs
Study: 9323505
Drug: 3 x
Normalized name: Xenon (133 xe)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 x 2 liter daily exchange
Study: 9323505
Drug: 4 daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 daily exchanges
Study: 8405010
Drug: Ipratropium 80
Normalized name: Ipratropium
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium 80 mg q.i.d.
Study: 31667338
Drug: Letrozole +
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Letrozole + Dasatinib (100 mg/day PO)
Study: 31667338
Drug: Letrozole (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole (2.5 mg/day PO)
Study: 30742373
Drug: Imidafenacin 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imidafenacin 0.1 mg, twice a day for 12 weeks
Study: 30742373
Drug: Tolterodine 2
Normalized name: tolterodine 2 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolterodine 2 mg, twice a day for 12 weeks
Study: 22520132
Drug: Pentavalent rotavirus
Normalized name: Vaccine product containing only live pentavalent Rotavirus antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentavalent rotavirus vaccine (PRV), RotaTeq(®), 3 doses at 6, 10, and 14 weeks of age
Study: 22520132
Drug: Pentavalent rotavirus
Normalized name: Vaccine product containing only live pentavalent Rotavirus antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentavalent rotavirus vaccine (PRV), RotaTeq(®)
Study: 15914134
Drug: ACIDFORM gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACIDFORM gel (2 mL applied at bedtime for 7 consecutive days)
Study: 9614476
Drug: Self-exposure treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-exposure treatment
Study: 9614476
Drug: Self-relaxation treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-relaxation treatment
Study: 2527971
Drug: Toremifene (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toremifene (doses of 20 to 400 mg/d)
Study: 27043224
Drug: Acarbose (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarbose (100 mg, t.i.d.)
Study: 27043224
Drug: Glibenclamide (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glibenclamide (5 mg, t.i.d.)
Study: 21897774
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment with position monitoring and supine alarm device
Study: 21897774
Drug: Inactive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive treatment (control)
Study: 16485885
Drug: Various treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various treatment modalities including chemopreventative, chemotherapeutic, destructive, and novel immunologic methods.
Study: 3293873
Drug: 0.125 mg
Normalized name: digoxin 0.125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.125 mg trimoprostil
Study: 3293873
Drug: 0.75 mg
Normalized name: propinox 0.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 mg trimoprostil
Study: 3293873
Drug: 3.0 mg
Normalized name: TOBRAMYCIN 3.0 mg in 1 mL OPHTHALMIC SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.0 mg trimoprostil
Study: 31882016
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment at 11 local and 4 distal acupuncture points for 20 min twice a week for 6 weeks (Control Group)
Study: 31882016
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment at 11 local and 4 distal acupuncture points for 20 min twice a week for 6 weeks + Palmijihwang‐hwan for 6 weeks (Treatment Group)
Study: 31882016
Drug: Treatment Group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment Group
Study: 29291695
Drug: Evidence-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evidence-based therapy delivered by trained frontline workers
Study: 24997748
Drug: Platelet-rich plasma
Normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-rich plasma (PRP) injections, 2 injections during the first 2 weeks after injury.
Study: 24997748
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (historical control from a randomized trial with nonoperative treatment).
Study: 19454638
Drug: Intramyocardial injection
Normalized name: ALCOHOL 80 mL in 100 mL INTRAEPICARDIAL LIQUID [80% Alcohol Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramyocardial injection of 100 x 10(6) autologous bone marrow‐derived mononuclear cells
Study: 10443645
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth Hormone (GH) treatment for 10 years
Study: 7805238
Drug: Nifedipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (20 mg TID)
Study: 7805238
Drug: 35% O2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35% O2 administration
Study: 478632
Drug: Inactivated influenza
Normalized name: influenza, inactivated, whole virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated influenza virus vaccine (H3ChN2Ch)
Study: 478632
Drug: Inactivated influenza
Normalized name: influenza, inactivated, whole virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated influenza virus vaccine (Heq1N2Ch)
Study: 7043175
Drug: Clopamide (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopamide (5 mg/day)
Study: 7043175
Drug: Clopamide (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopamide (5 mg/day) + Pindolol (10 mg/day)
Study: 31961417
Drug: Lotion sunscreen
Normalized name: Hawaiian Tropic Lotion Sunscreen SPF 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lotion sunscreen
Study: 31961417
Drug: Aerosol spray
Normalized name: Betadine Aerosol Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosol spray sunscreen
Study: 31961417
Drug: Pump spray
Normalized name: FungiCURE Pump Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pump spray sunscreen
Study: 19188394
Drug: High-dose cefepime,
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cefepime, 2 g every 8 h (3-h infusion)
Study: 11802750
Drug: Lansoprazole (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole (15 mg once daily)
Study: 11802750
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment groups (misoprostol and lansoprazole)
Study: 8772218
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of gelatin
Study: 29786964
Drug: Laquinimod 1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laquinimod 1.2 mg/day
Study: 29786964
Drug: Moxifloxacin 400
Normalized name: moxifloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin 400 mg on day 14
Study: 23413906
Drug: Thymopetidum (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymopetidum (20 mg intramuscular injection, once every other day for 3 months)
Study: 19807760
Drug: Small-particle NASHA
Normalized name: Smallpox (Vaccinia) Vaccine, Live
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small-particle NASHA gel
Study: 19807760
Drug: Large-particle NASHA
Normalized name: Bos taurus large intestine preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Large-particle NASHA gel
Study: 17325686
Drug: Glucose drink
Normalized name: Dextrose 15 GM Oral Solution [RELION GLUCOSE DRINK]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose drink (75 g/300 ml)
Study: 11848167
Drug: Regular alcohol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular alcohol consumption (mean daily intake of 66.5 ± 4.7 ml)
Study: 11848167
Drug: Alcohol restriction
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol restriction (mean daily intake of 10.2 ± 1.9 ml)
Study: 10607247
Drug: Daily IFN-alpha
Normalized name: IFN .ALPHA.-1B
DrugBank: Interferon alfa-1b (DB18522)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily IFN-alpha (3 MU daily for 3 months followed by t.i.w. for 3 months)
Study: 10607247
Drug: Thrice weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrice weekly IFN-alpha (3 MU t.i.w. for 6 months)
Study: 10607247
Drug: Daily IFN-alpha
Normalized name: IFN .ALPHA.-1B
DrugBank: Interferon alfa-1b (DB18522)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily IFN-alpha
Study: 10607247
Drug: Thrice weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrice weekly IFN-alpha
Study: 10607247
Drug: Daily IFN-alpha
Normalized name: IFN .ALPHA.-1B
DrugBank: Interferon alfa-1b (DB18522)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily IFN-alpha (for patients infected with HCV types other than HCV-1)
Study: 10607247
Drug: Thrice weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrice weekly IFN-alpha (for patients infected with HCV types other than HCV-1)
Study: 26696273
Drug: Nicotine inhalator
Normalized name: nicotine Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine inhalator (Nicorette(®); 15 mg)
Study: 26696273
Drug: Conventional cigarette
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional cigarette (CC; JPS Silver King Size, 0.6 mg)
Study: 18557715
Drug: Noradrenaline 0.5-3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noradrenaline 0.5-3.0 mg/h and albumin (group A)
Study: 18557715
Drug: Terlipressin 0.5-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terlipressin 0.5-2 mg, 6 hourly and albumin (group B)
Study: 10462251
Drug: Vaccine containing
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine containing three recombinant malaria antigens (MSP1 190LCS.T3, MSP2, RESA) with Montanide ISA720 adjuvant
Study: 10462251
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of antigens
Study: 9050705
Drug: Topical anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anesthesia with 2% mepivacaine
Study: 1860020
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg fluphenazine decanoate every two weeks
Study: 1860020
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg fluphenazine decanoate every two weeks
Study: 6352119
Drug: Oxprenolol once
Normalized name: oxprenolol
DrugBank: Oxprenolol (DB01580)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxprenolol once daily (160-480 mg)
Study: 6352119
Drug: Oxprenolol twice
Normalized name: oxprenolol
DrugBank: Oxprenolol (DB01580)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxprenolol twice daily (160-480 mg)
Study: 6352119
Drug: Oxprenolol once
Normalized name: oxprenolol
DrugBank: Oxprenolol (DB01580)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxprenolol once daily
Study: 6352119
Drug: Oxprenolol twice
Normalized name: oxprenolol
DrugBank: Oxprenolol (DB01580)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxprenolol twice daily
Study: 31021358
Drug: Essential Amino
Normalized name: Essential amino acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Essential Amino Acids (EAA)-based multi-ingredient nutritional supplement
Study: 30235653
Drug: Neoadjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant therapy (specifics not provided)
Study: 20548096
Drug: R-CHOP therapy
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-CHOP therapy (rituximab plus CHOP)
Study: 20548096
Drug: CHOP therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHOP therapy (standard CHOP chemotherapy)
Study: 9923794
Drug: TPN plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPN plus daily injections of GH
Study: 9923794
Drug: GH and
Normalized name: Cough And Cold
DrugBank: Chlorpheniramine (DB01114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH and insulin combined with TPN
Study: 3929312
Drug: Buprenorphine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine (0.5 - 8.0 mg/day)
Study: 7352279
Drug: Buprenorphine (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine (8 mg/day)
Study: 3929312
Drug: Placebo buprenorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo buprenorphine plus heroin self-administration
Study: 29607525
Drug: LOC remission
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LOC remission at end-of-treatment
Study: 26733703
Drug: Daily lottery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily lottery incentive ($550 incentive)
Study: 26369563
Drug: Tiotropium Respimat®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium Respimat® 2.5 μg
Study: 24890738
Drug: Tiotropium Respimat®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium Respimat® 1.25 μg
Study: 12827578
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with antioxidants (vitamin E, vitamin C, allopurinol, and acetylcysteine)
Study: 10857897
Drug: High-dose intensification
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intensification (HDCVP): six courses of FAC followed by two courses of cyclophosphamide (5.25 g/m2), etoposide (1,500 mg/m2), and cisplatin (165 mg/m2)
Study: 10857897
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose chemotherapy (FAC): 5-fluorouracil, doxorubicin, and cyclophosphamide every 3 weeks for nine courses (control)
Study: 27355239
Drug: IONIS‐TTRRx (ISIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: IONIS‐TTRRx (ISIS 420915), a 2nd‐Generation 2'‐O‐(2‐methoxyethyl) modified antisense oligonucleotide (ASO) targeting TTR RNA transcript, administered for four weeks.
Study: 24796766
Drug: DHEA (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA (25 mg three times a day)
Study: 20236550
Drug: High tidal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High tidal volume (VT of 10 to 12 ml/kg predicted body weight)
Study: 20236550
Drug: Low tidal
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low tidal volume (VT of 5 to 7 ml/kg predicted body weight)
Study: 18608197
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg losartan (ARB)
Study: 18608197
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg amlodipine (CCB)
Study: 2686427
Drug: Ciprofloxacin 300
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin 300 mg IV
Study: 2686427
Drug: Cefotaxime 1000
Normalized name: cefotaxime 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime 1000 mg IV
Study: 31000133
Drug: Paracetamol (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol (500 mg) every 4 hours when body temperature exceeded 38°C during hospitalisation
Study: 31000133
Drug: Placebo (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (500 mg) every 4 hours when body temperature exceeded 38°C during hospitalisation
Study: 3044874
Drug: Paracetamol (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol (500 mg)
Study: 28503826
Drug: Extended chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended chemoradiotherapy (XCRT) - three cycles of fluorouracil based chemotherapy during a 10 week wait period
Study: 25910950
Drug: RT and
Normalized name: Comfort and Ease KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT and temozolomide with vandetanib (100 mg daily)
Study: 23422380
Drug: Duloxetine (DLX)
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Duloxetine (DLX) 60 mg once daily for 11 days
Study: 23422380
Drug: Escitalopram (ESC)
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Escitalopram (ESC) 20 mg once daily for 11 days
Study: 14975456
Drug: Antiproliferative drug‐eluting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiproliferative drug‐eluting stents (DES)
Study: 11452321
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B vaccine administered in the buttock (n = 123)
Study: 11452321
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B vaccine administered in the anterolateral thigh muscle (n = 135)
Study: 9610531
Drug: 0.4 mg/h
Normalized name: nitroglycerin 0.4 MG/HR
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg/h transdermal nitroglycerin (NTG) patches
Study: 7933697
Drug: Intravitreal hemocoagulase
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal hemocoagulase (1 NIH thrombin unit/100 ml in BSS Plus)
Study: 3074462
Drug: Norfloxacin 200
Normalized name: Norfloxacin
DrugBank: Norfloxacin (DB01059)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norfloxacin 200 mg b.i.d. for lower UTI; 400 mg b.i.d. for upper UTI
Study: 3074462
Drug: Co-trimoxazole (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-trimoxazole (160 mg of trimethoprim plus 800 mg of sulphamethoxazole) b.i.d. for seven days
Study: 412580
Drug: Adjuvant topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant topical mechlorethamine after electron beam therapy
Study: 412580
Drug: Electron beam
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electron beam therapy alone
Study: 31025260
Drug: Diet containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet containing 108 CFU g−1 Lactobacillus bulgaricus
Study: 30903342
Drug: Group C
Normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C (15 mg/kg IV TXA given on induction, additional doses at 3 hours and 6 hours post-incision)
Study: 30903342
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B (15 mg/kg IV TXA given on induction, additional dose at 3 hours post-incision)
Study: 30903342
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A (15 mg/kg IV TXA given on induction)
Study: 25573400
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (2.5 mg/d), vitamin B6 (50 mg/d), and vitamin B12 (1 mg/d)
Study: 22777119
Drug: Continuous Parenteral
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous Parenteral Nutrition (PN)
Study: 7908013
Drug: Taxol at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taxol at doses ranging between 135 and 175 mg/m2, administered via 3-hour infusion
Study: 7908013
Drug: Taxol at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taxol at doses ranging between 135 and 175 mg/m2, administered via 24-hour infusion
Study: 7908013
Drug: Taxol at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taxol at higher dose levels and with prolonged infusion
Study: 2817461
Drug: Transdermal scopolamine
Normalized name: Transderm Scop
DrugBank: Scopolamine (DB00747)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal scopolamine (TDS)